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Abstract: In many stroke patients it is not possible to establish the etiology of stroke. However, in the last two decades, 
the use of transesophageal echocardiography in patients with stroke of uncertain etiology reveals atherosclerotic plaques 
in the aortic arch, which often protrude into the lumen and have mobile components in a high percentage of cases. Several 
autopsy series and retrospective studies of cases and controls have shown an association between aortic arch atheroma and 
arterial embolism, which was later confirmed by prospectively designed studies. The association with ischemic stroke was 
particularly strong when atheromas were located proximal to the ostium of the left subclavian artery, when the plaque was 
 4 mm thick and particularly when mobile components are present. In these cases, aspirin might not prevent adequately 
new arterial ischemic events especially stroke. Here we review the evidence of aortic arch atheroma as an independent 
risk factor for stroke and arterial embolism, including clinical and pathological data on atherosclerosis of the thoracic 
aorta as an embolic source. In addition, the impact of complex plaques ( 4 mm thick, or with mobile components) on 
increasing the risk of stroke is also reviewed. In non-randomized retrospective studies anticoagulation was superior to 
antiplatelet therapy in patients with stroke and aortic arch plaques with mobile components. In a retrospective case-control 
study, statins significantly reduced the relative risk of new vascular events. However, given the limited data available and 
its retrospective nature, randomized prospective studies are needed to establish the optimal secondary prevention 
therapeutic regimens in these high risk patients. 
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INTRODUCTION 
  With the progressive increase in life expectancy in 
Western populations, the incidence of cerebral ischemic 
diseases has become a direct cause of death of 10% of the 
general population. In addition, another 10% of deaths are 
related to the consequences and complications following 
cerebral infarction.  
  In the first half of the 20th century, it was considered that 
the majority of cerebral infarctions were due to an episode of 
vasospasm, but currently this mechanism is not considered of 
great importance. Basically, this view has changed since 
1951, when C. Miller Fisher described the trascendental 
etiological role of artery-artery embolism from carotid 
atherosclerotic plaques [1]. Subsequently, it has been shown 
that approximately 25% of cerebral ischemic events are due 
to cardioembolism [2] with atrial fibrillation involved in two 
thirds of these patients [2], which is a relevant finding to 
establish a correct diagnosis given the need of anticoagu-
lation and the increasing trend to start anticoagulants very 
early [3,4]. Because of the importance of both etiologies, 
most current protocols for assessing cerebral ischemia 
include specific radioimaging studies of the cranial arterial 
system (Doppler ultrasound evaluation of supra-aortic 
arteries, optionally in association with angiography or mag-
netic resonance angiography), as well as cardiological 
studies including electrocardiogram, transthoracic echocar-
diogram (TTE), and Holter electrocardiographic   
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monitoring if paroxysmal atrial arrhythmias are suspected. 
Despite the use of these diagnostic studies together with 
routine screening of possible coagulopathy or systemic 
diseases, and the use of transcranial Doppler sonography 
with the Valsalva maneuver to rule out the presence of patent 
foramen ovale with right-to-left shunt, it is not possible to 
establish a definitive etiologic diagnosis in 10-40% of 
ischemic stroke patients [5-8]. 
  The management of patients with cerebral infarction 
focuses on measures that will reduce the risk of stroke recur-
rence. These secondary prevention strategies include quitting 
smoking, the administration of aspirin, antihypertensive and 
lipid-lowering treatments to reduce blood pressure and 
cholesterol (even when in the "normal" range), surgical or 
percutaneous interventions on significant stenosis of the 
symptomatic carotid artery, and anticoagulation in the case 
of cardioembolism. However, in the context of secondary 
prevention it is essential to reach an etiological diagnosis in 
order to prescribe the optimal measures for each individual 
patient, and in this respect, stroke of uncertain etiology 
remains a great clinical challenge. Between the heart and the 
carotid and vertebral arteries there is the aortic arch, an area 
of difficult access for diagnostic techniques commonly used 
in daily practice. In recent years data have been emerging on 
the association of aortic arch atheromas and cerebral 
infraction, in particular, when no obvious etiology could be 
found. Thus, there is an increasingly perception of this 
particular vascular territory as the “missing link” responsible 
for most of the cerebral infarctions of undetermined cause, 
and it is particularly evident in case of recurrent ischemic 
cerebral events despite the use of adequate general treatment 
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AORTIC ARCH ATHEROMATOSIS 
  Aortic arch atheroma can be seen in some young adults 
but its incidence and severity increases with age [9, 10]. This 
condition is associated with smoking, hypercholesterolemia, 
hypertension, diabetes, male sex, and elevated plasma levels 
of fibrinogen and homocysteine [11, 12]. Its natural history 
is very variable and not always progressive. In three 
echographic studies of the morphological changes of aortic 
arch atheromas at 6-12 months of follow-up, plaque thick-
ness had increased in 8%, 23% and 37% of lesions, but it 
improved in 2%, 10% and 22%, and remained unchanged in 
41%, 67% and 90% of the cases, respectively [10, 13, 14]. 
These data suggest that atheromatosis is a dynamic process 
and that although plaque regression is possible, the most 
likely clinical course is slow progression. 
  In the first half of the past century, some pathologists 
suggested that "eroded atherosclerotic plaques" could result 
in embolic arterial occlusions [15], and in the 60s some case 
reports supporting this concept were published [16, 17]. 
However, these findings could not be assessed in vivo until 
the introduction of transesophageal echocardiography (TEE) 
in the 80s, --a highly complex imaging technique minimally 
invasive, with a very low risk of complications--, which 
permits to directly visualize some cardiac and vascular 
structures previously inaccessible (e.g., the aortic arch). In 
1990, Tunick and Kronzon [18] reported the cases of three 
patients of 68, 70 and 77 years of age, respectively, presen-
ting with acute cerebral ischemia (in one case associated to 
peripheral arterial embolism), in whom TEE documented 
large atheromatous plaques which protruded strikingly into 
the aortic arch lumen and had obvious mobile components, 
the probable etiology of embolism being attributed to them. 
PREVALENCE OF AORTIC ARCH ATHEROMA 
  In a series of 2700 autopsies of patients between 15 and 
64 years of age who died in New Orleans between 1960 and 
1968 by external violence or natural causes other than 
coronary heart disease, stroke, diabetes or hypertension, the 
prevalence of aortic plaques increased with age from 0.4% at 
15-24 years of age up to 33% at 55-64 years [19]. The Stroke 
Prevention Assessment of Risk in the Community (SPARC) 
study [20], a random sample of 581 people over age of 44 
years in Olmstead County Minnesota, was evaluated. All 
participants had TEE and atheroma was identified in 51.3% 
of patients, been characterized as severe atheroma in 7.6% 
(plaque thickness  4 mm, ulcerated, or with mobile com-
ponent). In this random population, the prevalence of 
complex aortic arch atheroma increased with age, with 
severe atheroma documented in more than 20% of patients 
older than 70 years. 
 Davila-Roman  et al. [9] analyzed perioperative epiaortic 
ultrasound examinations in 1200 patients of more than 49 
years of age having open heart surgery (88% of them having 
coronary artery bypass grafting). In this series, complex 
plaques (plaque thickness  3 mm, ulcerated or mobile 
components) were found in 19.3% of patients, and its 
prevalence increased with age (from 9.6% in the range 
between 50-60 years to 32.6% in patients over 80 years). The 
fact that in this series the prevalence of complex plaques was 
greater than that recorded in the SPARC study [20] (19.3% 
vs 7.6%) could be attributed both to the selection of patients 
(88% with coronary artery disease) and to the inclusion as 
“complex plaque” of atheromas between 3 and 3.9 mm of 
plaque thickness. 
PREVALENCE OF AORTIC ARCH ATHEROMA IN 
PATIENTS WITH STROKE  
Autopsy Studies 
  In 1992, Amarenco et al. [21] published a review of 500 
consecutive autopsies in patients with neurological diseases. 
Ulcerated plaques were documented in the aortic arch in 62 
of 239 (26%) patients who died from stroke but in only 13 of 
261 (5%) patients who died from other neurological diseases 
(P < 0.001). Interestingly, such plaques were seen in 17 of 
28 (61%) patients who died from cerebral infarction of 
unknown etiology as compared to only 34 of 155 (22%) 
patients with an identifiable cause of ischemic stroke (P 
<0.001). 
  In a series of 120 consecutive hospital autopsies, Khati-
bzadeh et al. [22] found 36 cases with pathological evidence 
of cerebral infarction. In a multiple linear regression 
analysis, stroke was associated with atrial fibrillation (hazard 
ratio [HR] = 3.5; 95% confidence interval [CI] 1.1- 9.9), 
ipsilateral carotid stenosis greater than 75% (HR = 11.7, 
95% CI 3.1-45.3), and complex plaques in the aortic arch 
(ulcerated, with mural thrombosis or atheromatous debris) 
(HR = 5.8, 95% CI 1.1–31.7). 
Non-Controlled Ultrasound Studies 
  As previously mentioned, Tunick and Kronzon [18], in 
1990, reported three patients with acute cerebral ischemia in 
whom assessment of the aortic arch by TEE showed large 
plaques with mobile components protruding into the lumen, 
and embolism was likely attributed to these lesions. In the 
same year, Pop et al. [23] reported TEE findings in 72 con-
secutive patients with stroke or transient cerebral ischemia, 
documenting aortic arch plaques in 32 (44.4%). In similar 
studies conducted in patients with cerebral ischemia, the 
prevalence of aortic arch plaques ranged between 14% and 
42% [24, 25]; in another study, plaques with endoluminal 
mobile components were documented in 4 of 183 patients 
[26]. 
Retrospective Case-Control Ultrasound Studies 
  Several retrospective studies of cases and controls found 
a significant association between stroke or peripheral 
embolism and aortic arch atheromas. In three studies based 
on TEE [27-29], the prevalence of aortic arch atheroma in 
patients with previous embolism ranged between 21% and 
27%, whereas ranged between 4% and 13 % in controls. The 
multivariate analysis showed that patients with aortic arch 
atheroma had a significantly higher prevalence of previous 
stroke (odds ratio [OR] between 3.2 and 8.2). On the other 
hand, in a study of 1200 perioperative epiaortic ultrasound 
studies in patients undergoing open heart surgery (coronary 
bypass surgery in 88% of the cases), Davila-Roman et al. [9] 
found that the prevalence of aortic arch atheroma was 
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transient cerebral ischemia than in those without history of 
cerebrovascular events (18%).  
  Nine studies [29-37] examined the prevalence of aortic 
arch atheroma in patients undergoing TEE for the evaluation 
of stroke or peripheral embolism, including patients referred 
for echocardiography for other reasons (controls). In these 
studies, when TEE showed the presence of aortic arch 
atheroma the OR of previous stroke or peripheral embolism 
ranged between 1.92 and 16.52. 
Plaque Morphology and Embolic Risk in Retrospective 
Case-Control Studies 
  The relationship between aortic arch atheroma and stroke 
is even more evident when the morphologic characteristics 
of the plaques are assessed. The most significant association 
relies on the presence of endovascular mobile components, 
its pedunculated appearance, plaque ulceration, and the 
highest degrees of plaque thickness. 
 Kazui  et al. [38] performed TEE in 62 patients with 
lacunar infarction and in 202 healthy controls and found 
aortic arch atheromas  5 mm thick in 20% of lacunar stroke 
patients compared with only in 4% in controls (OR = 5.94, 
95% CI 2.30-15.32). Karalis et al. [39] reviewed 556 
unselected TEE studies and documented previous stroke or 
peripheral embolism in 11 of 36 (30.6%) patients with aortic 
arch complex plaques ( 5 mm thick) in comparison with 4 
of 100 (4%) age-matched controls without complex aortic 
arch plaques. In this study, plaque morphology also seemed 
to be important, with previous stroke or arterial embolism in 
8 of 11 (72.7%) patients with pedunculated mobile 
atheromas and in only 3 of 25 (12%) patients with immobile 
plaques. In a case-control study, Tunick et al. [27] evaluated 
122 patients referred to TEE for evaluation of stroke, 
transient cerebral ischemia, or unexplained arterial embolism 
and 122 controls matched for age and sex referred for other 
reasons. Complex aortic arch atheroma ( 5 mm in plaque 
thickness or presence of mobile components) was found in 
33 of 122 (27%) cases compared with in 11 of 122 (9%) 
controls (OR = 3.74, 95% CI 1.79-7.82). Mobile atheroma 
was observed in 11 of 122 cases (9%) and in none of patients 
in the control group. 
  In five patients with mobile lesions it was demostrated at 
the time of surgery that the moving images corresponded to 
thrombi attached to ulcerated or fissured atherosclerotic 
plaques [35, 40, 41]. Likewise, it has been described the 
disappearance of these mobile lesions after anticoagulation 
[42, 43] and thrombolysis [44]. The most remarkable com-
mon finding in all these observational or retrospective 
studies in patients with stroke or peripheral embolism is the 
high prevalence of atherosclerosis of the aortic arch 
(between 20% and 30%), which results of similar (or even 
greater) magnitude than the prevalence of carotid artery 
stenosis or atrial fibrillation in patients with stroke [5, 28, 
45]. 
  Besides plaque thickness and the presence of moving 
components, plaque ulceration also confers poor prognosis. 
In an autopsy study [21], ulcerated aortic arch plaques were 
found in 61% of 28 patients with stroke of uncertain cause as 
compared with in only 22% of 155 stroke patients with an 
apparently obvious etiology of stroke (P < 0.001); after 
adjusting by covariates, the prevalence of plaque ulceration 
was 57.8% and 20.2%, respectively (adjusted OR = 5.7, 95% 
CI 2.4-13.6, P < 0.001). In a TEE study [32] the presence of 
plaque ulceration ( 2 mm) was highly correlated with 
cryptogenic stroke. Thus, ulcerated plaques were found in 9 
of 23 patients (39.1%) with stroke of unknown etiology as 
compared with 2 of 26 patients (7.7%) with an identifiable 
cause of stroke, and in only 4 of 57 patients (7%) with no 
clinical history of stroke. 
  Despite the strong association between atheroma of the 
aortic arch and embolism, which is particularly evident in the 
case of thickest plaques and those with moving components 
and/or ulceration, causality could not be definitely estab-
lished because these data were basically descriptive or had 
been obtained retrospectively. 
AORTIC ARCH ATHEROMA AS A PROBABLE 
CAUSE OF STROKE 
Causality and Anatomical Location of Atheromas 
  The SPARC study [45] included a random population of 
585 patients at high risk of vascular events in which TEE 
data were obtained. The mean age was 66.9 years, and aortic 
plaques were detected in at least one of the three aortic 
segments (ascending, arch, and descending) in 252 patients 
(43.1%). In 44 cases (7.5%), plaques were morphologically 
complex ( 4 mm thick, ulcerated, or with mobile com-
ponents). The prevalence of simple and complex plaques in 
the ascending aorta was 8.4% and 0.2%, respectively, but in 
the aortic arch the prevalence increased to 31.0% and 2.2%, 
and in the descending aorta to 43.7% and 6.0%. Therefore, 
the great majority of simple (90.1%) and complex (97.6%) 
aortic arch atheromas are located distally to the innominate 
artery. It is particularly interesting that only 18% of embolic 
events involved the right brain (versus 82% the left brain or 
peripheral arteries) [27], and since it is not expected for 
atheromas located distal to the innominate artery to develop 
retrograde embolization to the right brain (except in the 
unlikely event of a severe aortic valve insufficiency), this 
observation also supports the hypothesis of causality for 
aortic arch atheroma in the pathogenesis of stroke and 
peripheral arterial embolism. 
Case-Control Studies 
  Prospective studies can overcome most of the limitations 
inherent to retrospective series (Table 1). In 1994, Amarenco 
et al. [46] reported a prospective case-control study which 
included 250 consecutive patients over 60 years of age 
referred for TEE during hospitalization for stroke, and 250 
consecutive controls over 60 years of age without previous 
stroke referred to TEE for valvular heart disease, ischemic 
heart disease, atrial fibrillation, or suspected endocarditis. 
The stroke patients were significantly older than controls 
(mean age 76 vs 72 years) and showed a higher occurrence 
of hypertension (67% vs 35%), hypercholesterolemia (31% 
vs 24%), cigarette smoking (41% vs 32 %), and diabetes 
(18% vs 12%). Patients with cerebral infarction had a higher 
prevalence of atheroma 1–3.9 mm thickness in the ascending 
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adjusting for cardiovascular risk factors, P < 0.001). In this 
study the prevalence of plaques  4 mm thick located in the 
ascending aorta or the aortic arch was also significantly 
higher in stroke patients than in controls (14.4% vs 2.0%, P 
<0.001), and after adjustment for cardiovascular risk factors, 
patients with plaques  4 mm thick showed a high risk for 
stroke (OR = 9.1). Moreover, the HR for cerebral infarction 
increased with plaque thickness, from 1.0 (no risk) for ather-
mas 0–1 mm thick to 4.4 (95% CI 2.8–6.8) for atheromas 1–
3.9 mm and to 13.8 (95% CI 5.2–36.1) for atheromas  4 
mm. In the subgroup of 78 patients with stroke of unde-
termined cause, the prevalence of plaques  4 mm thick was 
28.2%, compared with only 8.1% in 172 patients with 
cerebral infarction in which the etiology of stroke was 
identified (OR = 4.7, 95% CI 2.2-10.1, P < 0.001). 
 Jones  et al. [28] reported a prospective case-control study 
that included patients of any age with stroke or transient 
ischemic attack referred for TEE and ambulatory controls. 
Patients had a higher prevalence of atrial fibrillation, hyper-
tension, smoking, diabetes, and carotid artery stenosis. In 
stroke patients, the adjusted OR for non-complex atheroma 
(< 5 mm plaque thickness) was 2.3 (95% IC 1.2–2.4) but 
when the analysis was restricted to complex plaques ( 5 
mm thick, ulcerated, or mobile components) the adjusted OR 
increased to 7.1 (95% CI 2.7-18.4). 
Table  1.  Data of Main Studies of Aortic Arch Atheroma in Stroke Patients or Patients Undergoing Transesophageal 
Echocardiography (TEE) Published in the Literature 
Studies  Population  Definition of Complex Plaque 
N 
(Cases/Controls) 
Association with Clinical Events 
After Adjustement 
Post-Mortem 
Amarenco et al. [21] 
Khatibzadeh et al. [22] 
 
Neuologic disease 
Unselected 
 
Ulcerated plaque 
Ulceration, mural thrombus 
 
500 
120 
 
Yes 
Yes 
Case Series 
Tunick and Kronzon[18] 
Davila-Roman et al. [9] 
Pop et al. [23] 
Fasseas et al. [24] 
Toyoda et al. [25] 
Horowitz et al. [26] 
Mitush et al. [31] 
 
TIA or stroke 
Cardiac surgery 
TIA or stroke 
Stroke 
Embolic stroke 
TIA or stroke 
Unselected TEE 
 
Mobile 
> 4 mm, ulceration, mobile 
Descriptive 
> 4 mm, ulceration, mobile 
> 3 mm, irregular 
Mobile 
> 5 mm, mobile 
 
3 
1.200 
72 
64 
62 
183 
375 
 
... 
Yes 
... 
... 
... 
... 
Yes 
Retrospective Case-Control 
Studies 
Tunick et al. [27] 
Di Tullio [29] 
Di Tullio [30]
 
Stone et al. [32] 
Nakayama et al. [34] 
Matsumura et al. [33]
 
Kazui et al. [38] 
 
 
Stroke or embolism 
Stroke 
Stroke 
Stroke 
Stroke 
Stroke 
Stroke 
 
 
> 5 mm 
> 5 mm, ulcerated or mobile 
> 5 mm, ulcerated or mobile 
> 2 mm or ulcerated 
Protruding, ulceration 
> 4 mm, mobile 
> 5 mm 
 
 
244 (122 / 122) 
220 
304 (152 / 152) 
106 (49 / 57) 
80 (45 / 35) 
451 (50 / 401) 
264 (62 / 202) 
 
 
Yes 
... 
Yes 
... 
... 
... 
Yes 
Prospective Case-Control Studies 
Jones et al. [28] 
Amarenco et al. [46]
 
 
TIA or stroke 
Stroke 
 
> 5 mm, ulcerated or mobile 
> 4 mm, ulcerated or mobile 
 
417 (215 / 202) 
500 (250 / 250) 
 
Yes 
Yes 
Prospective Follow-Up Studies 
Ferrari et al. [37] 
Tunick et al. [47] 
FAPS group [49] 
Mitush et al. [48] 
Pujadas et al. [53] 
 
Unselected TEE 
Unselected TEE 
Stroke 
Unselected TEE 
Stroke unknown 
cause 
 
> 4 mm, mobile 
> 5 mm 
> 4 mm 
> 5 mm, mobile 
> 4 mm, mobile 
 
129 
84 (42 / 42) 
331 (45 / 286) 
183 (47 / 136) 
 350 (248 / 102) 
 
Yes 
Yes 
Yes 
Yes 
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Follow-Up Studies: Plaque Thickness, Morphology, and 
Embolic Risk 
  In the initial prospective studies (Table 1), plaque 
thickness  5 mm was used as the main criterion to define 
complex atheroma [27, 39]. In 1994, Tunick et al. [47] 
reported a prospective case-control study involving 42 
patients with complex plaques ( 5 mm thick or presence of 
mobile components) without evidence of other possible 
causes of embolism. These patients were selected from 521 
consecutive patients undergoing TEE over 1-year period. A 
group of 42 controls with comparable age, sex, and 
prevalence of hypertension referred for TEE without 
previous embolism, complex aortic plaques, carotid arterial 
disease or heart diseases associated with embolic risk was 
included. During an average follow-up period of 14 months, 
14 patients with complex atheromas had vascular events 
(33.3%) compared with only 3 controls (7.1%). In the multi-
variate analysis, complex atheroma was the only independent 
risk factor for vascular events (HR = 4.6, 95% CI 1.1-18.9). 
Similarly, in the study of Mitush et al. [48] during a median 
follow-up of 16 months patients with complex aortic arch 
plaques in the baseline TEE ( 5 mm thick, or mobile 
components) had a prevalence of systemic embolism of 18.9 
per 100 patient-years (11 of 47) compared with only 4.6 per 
100 patient-years (8 of 136) in controls without complex 
plaques. 
  The largest study was the French Study of Aortic Plaque 
in Stroke (FSAPS) Group [49], in which 331 consecutive 
stroke patients aged  60 years were followed for 2 to 4 
years. All patients had an initial TEE to assess the presence 
of atherosclerotic plaques in the aortic arch proximal to the 
ostium of the left subclavian artery. Patients were stratified 
into three groups depending on aortic plaque thickness (<1 
mm, 1 to 3.9 mm, and  4 mm). At follow-up, the group of 
patients with plaques  4 mm showed an incidence of 11.9 
strokes per 100 patient-years as compared with 3.5 per 100 
patient-years in patients with plaques between 1 and 3.9 mm, 
and 2.8 per 100 patient-years in those with plaques < 1 mm 
(P <0.001). The incidence of any arterial vascular event in 
the three study groups was 26.0, 9,1, and 5.9 per 100 patient-
years, respectively (P < 0.001). After adjustment for the 
presence of carotid stenosis, atrial fibrillation, peripheral 
arterial disease, and other risk factors, plaque thickness  4 
mm was an independent predictor of both recurrent stroke 
(relative risk [RR = 3.8, 95% CI 1.8–7.8, P = 0.0012) and 
any new arterial vascular event (RR = 3.5, 95% CI 2.1–5.9, 
P < 0.001). The presence of plaques  4 mm thick in the 
descending thoracic aorta (which theoretically cannot 
embolize retrogradely to the brain) was associated with an 
OR for ratio for stroke of 1.5, whereas identical plaques 
located proximal to the ostium of the left subclavian artery 
were associated with an OR of 13.8. This finding also 
supports the concept of causality of aortic arch complex 
plaques and cerebral embolism. 
  Since the FSAPS study [49], it has been accepted that the 
two main criteria for embolic risk associated with aortic arch 
atheromas are plaque thickness  4 mm and the presence of 
mobile components. During three consecutive years Ferrari 
et al. [37] performed 1116 TEE and observed aortic arch 
atheromas in 139 patients (85% of whom had been referred 
by an embolic event). These patients were followed for a 
mean of 22 months. At follow-up, patients with plaques 1–
3.9 mm thick (n = 45, group I) had an incidence of stroke, 
peripheral embolism, or death of 8.8% compared with 24.0% 
in patients with plaques  4 mm thick (n = 50, group II) and 
39.2% in those with mobile components irrespective of 
plaque thickness (n = 34, group III) (P = 0.007). When the 
analysis was limited to mortality, significantly higher rates 
were obtained in patients with documented mobile plaque 
components (P = 0.049). 
 Cohen  et al. [50] followed 334 patients  60 years of age 
which had a TEE immediately after a stroke for 2 to 4 years. 
In this study, patients with plaque thickness  4 mm without 
echocardiographically detectable calcification had a higher 
incidence of vascular events, reaching a RR of 10.3. The 
same findings were obtained in a study of coronary artery 
bypass graft surgery [51]. Hypoechoic plaques were asso-
ciated with an increased incidence of perioperative stroke 
and embolic events. Possibly hypoechoic plaques (not 
calcified) have high lipid content, would be more easily 
fissured, and generation of superimposed thrombosis. In a 
histological study, it was found that plaques associated with 
thrombi were those with its highest volume proportion 
occupied by extracellular lipids, and with greater numbers of 
monocytes and macrophages at the level of the capsule [52]. 
  All these data demonstrate a strong independent asso-
ciation between ischemic stroke and aortic arch atheroma 
located proximal to the ostium of the left subclavian artery, 
which is very suggestive of causality. This association is 
particularly evident in patients with stroke of unknown 
etiology, which also supports the view of causality. Plaque 
morphology is a powerful marker of embolic risk, being 
particularly high in the thickest plaques, when moving 
components are detectable, and possibly in the presence of 
ulceration and hypoechogenic echographic characteristics. 
Prospective Follow-Up Studies of Cerebral Infarction of 
Unknown Etiology 
  In a Spanish study, 1840 consecutive patients with a first-
ever stroke were evaluated through a diagnostic protocol 
restrictive for TEE practice [53], and in 248 cases (13,5%) it 
was not possible to establish a definite etiologic diagnosis. 
This subgroup of patients received aspirin 300 mg/day over 
1-year. TEE in association with all diagnostic work-up 
studies were repeated in 20 (8.1%) patients who developed a 
new arterial ischemic episode at follow-up (recurrent stroke 
in 13, transient cerebral ischemia in 3). All new events 
occurred within the first 4 months of follow-up. Except for 
TEE the remaining diagnostic studies were unrevealing. TEE 
showed complex plaques proximal to the ostium of the left 
subclavian artery in 15 of the 20 patients (75%) (10 cases 
with presence of mobiles components; 5 cases with both  4 
mm plaque thickness plus plaque ulceration). On the other 
hand, the control group of the FSAPS population [49] (in 
which TEE was performed at baseline in all the 331 stroke 
patients included) was similar to the Spanish population with 
regard to age (75.7 vs 75.4 years), gender distribution, and 
prevalence of major cardiovascular risk factors (hyperten-
sion, hyperlipidemia, diabetes, smoking, atrial fibrillation, 
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disease). Both studies used the same criteria for classifying 
patients as stroke of unknown etiology (no etiological 
diagnosis regardless of the presence or absence of aortic 
plaques), treated these patients with antiplatelet agents, and 
reported a similar incidence of recurrence of stroke and 
arterial embolism during follow-up. The Spanish patients 
with recurrent cerebral infarction of unknown etiology had a 
prevalence of complex aortic arch plaques of 82.4% 
compared with 21.1 % in the FSAPS patients with cerebral 
infarction of uncertain etiology treated with antiplatelet 
drugs who had no recurrence of stroke (P < 0.0001). These 
data also suggest an etiological role for complex aortic 
plaques and stroke especially when an identifiable cause is 
lacking, and in the case of embolic recurrence during treat-
ment with aspirin. This observation seems particularly 
relevant for health care systems with accessibility limitations 
to TEE, which occurs especially in the context of geriatric 
stroke patients. 
IMAGING TECHNIQUES 
  TTE allows visualization of the aortic root and proximal 
ascending aorta. In some patients transcutaneous harmonic 
imaging from the suprasternal windows can reliably 
visualize protruding aortic arch atheromas, representing an 
excellent screening test and providing complementary views 
of regions which may be blind for TEE [54]. However, TEE 
is more accurate than TTE for detection of aortic arch 
atheromas and its mobile components (Fig. 1), measuring 
plaque thickness and ulceration, and to define qualitatively 
its echogenicity, including the presence of calcification [55]. 
  Magnetic resonance imaging (MRI) can provide impor-
tant information on the characteristics of the atheromatous 
plaque and its component tissues, including the presence of 
calcification, fibrocellular tissue, lipid composition, and 
presence of thrombus [56, 57]. Stability of the plaque 
depends on the size of the lipid core, the thickness of the 
fibrous capsule, and the presence of inflammation, MRI 
offering the ability to provide valuable information on these 
three parameters [58]. However, in a comparative study with 
TEE, MRI underestimated the thickness of the plaques 
located at the aortic arch probably because of the difficulty 
in accurately defining its external limit in the angio-MRI 
[59]. However, this technique is expensive and not feasible 
in critically ill patients with stroke and neurologically 
unstable clinical circumstances, has frequent contraindi-
cations (prostheses, pacemakers, defibrillators, claustro-
phobia), and is less reliable than TEE for detection of mobile 
thrombi (which is the most powerful predictor of embolism). 
Therefore, MRI should not be considered a suitable tech-
nique for the routine study of these patients. 
  Computed tomography (CT) scanning is useful in 
evaluating the aorta and its major branches. The high-
resolution helical CT allows detection of protruding aortic 
plaques and would be of particular interest in the study of 
areas not visualized by TEE (e.g., the distal ascending aorta). 
In two studies [60, 61], CT detected 94% and 95% of the 
plaques documented by TEE being also able to reliably 
assess plaque thickness. Finally, the combination of CT with 
positron emitting tomography (PET) allows fluorodeoxy-
glucose uptake in aortic atherosclerotic plaques to identify 
unstable plaques [62, 63]. 
  In any case, the cost, complexity, technical problems, and 
limited accessibility to MRI and CT determine that TEE has 
to be considered as the technique of choice (gold standard) in 
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the diagnosis of atherosclerotic plaques of the aortic arch as 
well as in the characterization of their morphological charac-
teristics for embolic risk stratification. However, in some 
patients with good transcutaneous suprasternal windows, 
TTE may be sufficient to diagnose and classify the embolic 
risk, and in this case it contributes with the advantages of 
simplicity, safety, low-cost, and the possibility to be made at 
the patient’s bedside in cases of acute cerebral infarction and 
unstable neurological conditions. 
COMPLEX AORTIC ARCH TREATMENT IN 
STROKE PATIENTS 
Surgical  
  There have been described isolated cases of surgical 
aortic arch endarterectomy in relatively young patients with 
complex aortic plaques and recurrent embolism despite 
anticoagulation [40, 41, 64]. Arko et al. [65] published a 
series of 23 patients with arterial embolism and aortic arch 
plaques with mobile components treated with surgical 
endarterectomy followed by warfarin; in 18 months of 
follow-up no new vascular events occurred and the mobile 
components had disappeared in all 6 patients who underwent 
a control TEE. However, in large clinical series it has been 
shown that aortic arch surgical endarterectomy is associated 
with an increased risk of extensive intraoperative cerebral 
infarction [66]. 
  Currently, there are no data supporting the widespread 
introduction of surgical endarterectomy of the aortic arch in 
these patients, but this technique should be restricted to 
patients with severe recurrent arterial embolism unrespon-
sive to anticoagulation and other supportive medical 
therapies. 
Treatment of Hypercholesterolemia 
  In patients with carotid or aortic arch atheromatosis, 
simvastatin reduces vascular wall thickness increasing the 
luminal area [67]. The Heart Protection Study [68] showed 
that simvastatin was effective in secondary prevention of 
vascular events in stroke patients even when plasma 
cholesterol levels were in the "normal" range. In accordance, 
the Cholesterol and Recurrent Events study (CARE) [69] 
included elderly patients with myocardial infarction and 
“normal” cholesterol levels, showing that treatment with 
pravastatin was associated with a clinically significant 
reduction in the risk of stroke and coronary events.  
  To date there are no randomized studies on the effect of 
statins in patients with complex atherosclerotic aortic 
plaques. The main information available comes from an 
observational study of 519 patients with complex aortic arch 
plaques diagnosed by TEE, which documented an incidence 
of embolic events of 21% during the follow-up [70]. 
Multivariate analysis showed that administration of a statin 
had an independent protective effect on embolic events with 
a RR reduction of 59% (P = 0.0001). A study controlled by 
MRI [71] showed regression of plaque thickness during 
statin therapy, and the intensity of this effect was 
significantly associated with the level of decrease in serum 
levels of LDL-cholesterol. Two further studies confirmed 
regression of plaque thickness during statin therapy; in one 
of them [72], this effect was only associated with the LDL-
cholesterol levels achieved, but in the other [73] regression 
was associated both with the level of LDL-cholesterol 
achieved and with the dose of statin administered. 
  Therefore, it seems very likely that statins reduce the risk 
of stroke in patients with complex plaques at the aortic arch. 
This could be related to its effects on plaque regression, 
plaque stabilization by reducing their lipid content, inhibition 
of inflammatory patterns in the lesion, and possible effects 
on coagulation. Consequently, statins should be administered 
to all stroke patients with complex aortic arch plaques 
independently of their plasma cholesterol levels, since part of 
the preventive benefits may be associated with the   
pleitropic effects of these compounds. 
Treatment of Hypertension 
  There are no available data on the effects of antihyper-
tensive therapy on the clinical course or potential regression 
of complex aortic arch plaques. Like the case of cholesterol, 
in the PROGRESS study [74] the association of indapamide 
and perindopril reduced blood pressure and was effective in 
the secondary prevention of stroke even in patients whose 
baseline blood pressure was within the "normal" range. 
Although there are no randomized studies, hypertensive 
stroke patients with complex aortic arch plaques are at high 
risk of recurrent ischemic stroke and, therefore, both 
hypertension and other concomitant cardiovascular risk 
factors should be adequately treated. 
Antithrombotic and Anticoagulant Treatment 
  It has been shown that moving components superimposed 
to plaques generally correspond to thrombus [35, 40-44], and 
that this is the greatest risk factor for recurrent embolism [37, 
53]. Accordingly, it seems logical to prescribe anticoagu-
lation to prevent further ischemic events. Although there are 
no randomized studies on anticoagulation in stroke patients 
with high risk aortic arch complex plaques, this treatment 
was beneficial in two major observational studies. Dressler et 
al. [75] reported a series of 31 patients with complex aortic 
arch plaques and mobile components detected by TEE in 
which anticoagulation reduced the incidence of vascular 
events. At follow-up, stroke occurred in 3 of 11 patients not 
treated with anticoagulants as compared with none in the 20 
patients treated with warfarin). Ferrari et al. [37] in a non-
randomized observational study of 129 patients with aortic 
arch atherosclerotic plaques, which were detected by TEE 
performed to examine potential embolic sources, anticoagu-
lation was associated with a significant reduction in embolic 
events (no emboli in 27 patients anticoagulated as compared 
with 5 strokes in 23 patients treated with platelet antiagre-
gants). Additionally, anticoagulation reduced mortality in the 
subgroup of patients with mobile plaque components. 
However, all these data must be interpreted with caution 
because both aforementioned studies were observational and 
retrospective and the study population was small. 
  It has been shown that treatment with aspirin reduces the 
risk of recurrent stroke. The meta-analysis of the Antiplatelet 
Trialists Collaboration [76] showed that treatment with 
aspirin during 3 years was associated with a risk reduction of 
vascular events from 22% to 18%. However, in some Complex Atheromatosis of the Aortic Arch in Cerebral Infarction  Current Cardiology Reviews, 2010, Vol. 6, No. 3    191 
patients with stroke and complex aortic arch plaques 
(especially when mobile components are seen), antiplatelet 
therapy with aspirin alone may be insufficient [37, 53]. In 
CAPRIE study [77], clopidogrel was superior to aspirin in 
patients with clinical manifestations of atherothrombotic 
disease, and the effect was particularly evident in some high 
risk subgroups. The CHARISMA study [78] evaluated the 
effect of adding clopidogrel to standard treatment with low-
dose aspirin, and a modest beneficial effect (in the limit of 
significance) for dual antiplatelet therapy was only detected 
when analysis was restricted to the subgroup of 12,153 
patients with already established cardiovascular disease 
(7.9% vs 6.9%; RR reduction of vascular events of 12.5%, 
95% CI 0.77-0.998, P = 0.046). The MATCH study [79] 
compared the association of aspirin plus clopidogrel versus 
clopidogrel alone in patients with recent ischemic stroke or 
transient ischemic events, and no significant differences in 
the incidence of vascular events were found. In patients with 
stroke and complex aortic arch atherosclerotic plaques, 
antiplatelet therapy that seems to be more attractive is the 
association of aspirin and clopidogrel but in the absence of 
randomized prospective studies its effect should be 
considered uncertain and its possible use debatable. 
CONCLUDING REMARKS 
  In patients with ischemic cerebral infarction in whom 
standard non-invasive studies cannot identify any etiology, 
TEE should be performed to rule out the presence of 
complex aortic arch plaques especially in patients with 
cardiovascular risk factors. There is a high risk of short-term 
further embolic events when complex aortic arch plaques are 
found ( 4 mm thick, or presence of mobile components) but 
an increased risk is also present in case of ulcerated lesions 
and hypoechogenic plaques (which probably represent high 
lipid content). In these patients at high risk, in addition to 
treatment with statins and correction of the potential cardio-
vascular risk factors, anticoagulation or dual antiplatelet 
therapy with aspirin and clopidogrel should be considered. In 
the absence of randomized trials comparing the antithrom-
botic efficacy of these treatments, the limited data available 
from non-randomized retrospective studies support anticoa-
gulation especially in the case of plaques with mobile 
components. Data provided in the near future by the ongoing 
ARCH international study [80] in which patients with 
ischemic stroke or peripheral arterial embolism and complex 
aortic arch plaques are randomized to treatment with 
warfarin or the combination of aspirin and clopidogrel will 
contribute to find final answers to all these questions. In 
particular, analysis in a pre-determined subset of patients 
with mobile atheroma will establish whether a more 
intensive antithrombotic treatment is required for these 
patients. 
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